Published in Ann Oncol on January 01, 2002
A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood (2009) 1.74
Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging (2007) 1.12
Imaging response assessment in oncology. Cancer Imaging (2006) 1.03
Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica (2012) 0.93
Detection of ABCC1 expression in classical Hodgkin lymphoma is associated with increased risk of treatment failure using standard chemotherapy protocols. J Hematol Oncol (2012) 0.90
Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. J Clin Oncol (2014) 0.88
The role of SPET and PET in monitoring tumour response to therapy. Eur J Nucl Med Mol Imaging (2003) 0.84
Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. Proc Natl Acad Sci U S A (1968) 8.67
Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science (1967) 8.62
A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med (1998) 8.24
Whole-genome association study of bipolar disorder. Mol Psychiatry (2008) 6.80
Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma. J Virol (1982) 5.49
Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med (1996) 5.14
Frequent patient-to-patient transmission of hepatitis C virus in a haematology ward. Lancet (1995) 5.07
Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst (1970) 3.94
Biotechnology awareness study, Part 1: Where scientists get their information. Bull Med Libr Assoc (1991) 3.85
Occurrence of Epstein-Barr virus genomes in human lymphoblastoid cell lines. Nat New Biol (1972) 3.84
The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol (1996) 3.68
Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol (1998) 3.64
Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature (1982) 3.26
Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA (1999) 3.14
A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn (2001) 3.10
Demonstration of a herpes group virus in cultures of peripheral leukocytes from patients with infectious mononucleosis. J Virol (1968) 3.09
Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst (1969) 3.07
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood (1998) 2.83
Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population. Int J Cancer (1982) 2.51
Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet (1986) 2.38
Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci U S A (2001) 2.33
A new approach to monitoring exercise training. J Strength Cond Res (2001) 2.30
Measles virus antibody in aqueous humour of patients with uveitis associated with multiple sclerosis. Lancet (1992) 2.26
European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17
Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. J Urol (1997) 2.14
Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst (1987) 2.12
Comparative study of cultured Burkitt tumor cells by immunofluorescence, autoradiography, and electron microscopy. J Virol (1967) 2.07
Prognostic importance of low c-erbB2 expression in breast tumors. J Natl Cancer Inst (1998) 2.00
Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Oncol (1985) 1.95
Effects of race and socioeconomic status on survival of 1,332 black, Hispanic, and white women with breast cancer. Ann Surg Oncol (1997) 1.88
Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab (2007) 1.87
Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood. Lancet (1997) 1.84
The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int (2007) 1.82
Survival after implantation of the cardioverter defibrillator. Am J Cardiol (1992) 1.76
Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol (2006) 1.74
Breast cancer: relationship between the size of the primary tumour and the probability of metastatic dissemination. Br J Cancer (1984) 1.71
Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut (2005) 1.70
Male gonadal dysfunction in patients with Hodgkin's disease prior to treatment. Ann Oncol (2001) 1.70
Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol (2000) 1.66
An epidemiologic study of risk factors in two teenage suicide clusters. JAMA (1989) 1.65
Laparoscopic removal of a large colonic lipoma. Report of a case. Dis Colon Rectum (1991) 1.64
Solid tumors in patients treated for Hodgkin's disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol (2004) 1.62
Immune deficiency in family members of patients with Hodgkin's disease. Cancer (1990) 1.61
Functional relationships and structural determinants of two bacteriophage T4 lysozymes: a soluble (gene e) and a baseplate-associated (gene 5) protein. New Biol (1989) 1.59
Depression-related cognitions: antecedent or consequence? J Abnorm Psychol (1981) 1.58
Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene (2012) 1.55
Immunophenotyping of low-grade B-cell lymphoma in blood and bone marrow: poor correlation between immunophenotype and cytological/histological classification. Br J Haematol (1993) 1.55
The natural history of breast cancer: implications for a screening strategy. Int J Radiat Oncol Biol Phys (1990) 1.55
Frequent amplification of the telomerase reverse transcriptase gene in human tumors. Cancer Res (2000) 1.52
Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol (1998) 1.52
Characteristics of Hodgkin's disease-derived cell lines. Cancer Treat Rep (1982) 1.51
Hodgkin's disease: establishment and characterization of four in vitro cell lies. J Cancer Res Clin Oncol (1981) 1.50
Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group. J Clin Oncol (1995) 1.50
Clinical significance of serum cytokine patterns during start of fever in patients with neutropenia. Br J Haematol (1995) 1.49
Clonal cell surface structures related to differentiation, activation and homing in B-cell chronic lymphocytic leukemia and monoclonal lymphocytosis of undetermined significance. Eur J Haematol (1989) 1.48
Evidence for the detection of the normal counterpart of Hodgkin and Sternberg-Reed cells. Hematol Oncol (1984) 1.47
Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: evidence from studies in patients with leukaemia. Lancet (1985) 1.46
Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol (2007) 1.45
Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood (1998) 1.45
Interleukin-10 mRNA expression in B-cell chronic lymphocytic leukaemia inversely correlates with progression of disease. Br J Haematol (1996) 1.45
C-group chromosome marker in long-term leukocyte cultures. J Natl Cancer Inst (1968) 1.43
Hodgkin's disease--environmental or genetic? N Engl J Med (1995) 1.43
STAT3 is constitutively activated in Hodgkin cell lines. Blood (2001) 1.42
Bioelectrical impedance analysis in HIV-infected patients treated with triple antiretroviral treatment. Am J Clin Nutr (1999) 1.42
Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene (2000) 1.41
Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med (2000) 1.40
Correlation of chromosomal aberrations in a myeloma cell line with tumorigenicity in nude mice. Blut (1981) 1.40
Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction. J Exp Med (2000) 1.40
[Unusual site of an embryonal rhabdomyosarcoma of the mesenchymal hepatic pedicle]. Ann Pathol (1999) 1.39
Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol (2000) 1.39
High platelet contamination in progenitor cell concentrates results in significantly lower CD34+ yield after immunoselection. Transfusion (2000) 1.39
Resting energy expenditure, weight loss, and altered body composition in HIV infection. Nutrition (1996) 1.38
European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. J Clin Oncol (2004) 1.37
Spectrum and prognosis of neurologic complications after hematopoietic transplantation. Neurology (2006) 1.32
Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (1998) 1.30
A powerful DNA extraction method and PCR for detection of microsporidia in clinical stool specimens. Clin Diagn Lab Immunol (1999) 1.26
Retracted Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol (2008) 1.26
Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol (2004) 1.23
Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol (2005) 1.22
The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer (2004) 1.22
Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee. J Clin Oncol (2005) 1.21
Detection of microsporidia (Enterocytozoon bieneusi) in intestinal biopsy specimens from human immunodeficiency virus-infected patients by PCR. J Clin Microbiol (1995) 1.21
Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood (2000) 1.20
Artificial sweeteners--do they bear a carcinogenic risk? Ann Oncol (2004) 1.20
Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood (1996) 1.20
Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol (2000) 1.19
Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients. Cancer J Sci Am (1997) 1.18
Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors. J Endocrinol (2002) 1.17
Screening patients in general practice with COPD for long-term domiciliary oxygen requirement using pulse oximetry. Respir Med (1998) 1.17